Introduction
Materials and methods
Patient characteristics and treatment protocol
DNA extraction and genotyping
Definitions
Statistical analysis
Results
Patients’ characteristics
Clinical Parameters | No.# | Genotype |
P
| Clinical Parameters | No.# | Genotype |
P
| ||
---|---|---|---|---|---|---|---|---|---|
AA | AG + GG | AA | AG/GG | ||||||
Gender | Bulky mass | ||||||||
Male | 83 | 24 | 59 | 0.542 | ≥10 cm | 18 | 5 | 13 | 1.000 |
Female | 81 | 20 | 61 | <10 cm | 146 | 39 | 107 | ||
Age | Localized | ||||||||
≤60 | 102 | 26 | 76 | 0.620 | yes | 25 | 7 | 18 | 0.886 |
>60 | 62 | 18 | 44 | no | 139 | 37 | 102 | ||
B symptoms | No Extra Nodal Site | ||||||||
positive | 62 | 14 | 48 | 0.338 | ≤1 | 122 | 31 | 91 | 0.484 |
negative | 102 | 30 | 72 | >1 | 42 | 13 | 29 | ||
LDH | Incidence site | ||||||||
positive | 77 | 20 | 57 | 0.816 | lymph node | 93 | 25 | 68 | 0.986 |
negative | 87 | 24 | 63 | extralymph | 71 | 19 | 52 | ||
β2-MG | IPI | ||||||||
positive | 49 | 10 | 39 | 0.203 | 0~2 | 114 | 29 | 85 | 0.544 |
negative | 106 | 32 | 74 | 3~5 | 50 | 15 | 33 | ||
Stage | Molecular subtypes | ||||||||
I~II | 75 | 19 | 56 | 0.691 | GCB | 28 | 6 | 22 | 0.872 |
III~IV | 89 | 25 | 39 | non-GCB | 113 | 26 | 87 |
C1qA 276 polymorphism
Patient characteristics according to C1qA allele status
Clinical parameters | No. # | Genotype | χ2 |
P Value
| |
---|---|---|---|---|---|
Non-GCB | |||||
β2-MG |
AA
|
AG + GG
| |||
positive | 35 | 3 | 32 | 6.357 | 0.012 |
negative | 72 | 22 | 50 | ||
B symptoms | |||||
positive | 48 | 7 | 41 | 3.344 | 0.067 |
negative | 65 | 19 | 46 | ||
GCB | |||||
β2-MG |
AA
|
AG + GG
| |||
positive | 4 | 2 | 2 | 0.218* | |
negative | 22 | 4 | 18 | ||
B symptoms | |||||
positive | 7 | 3 | 4 | 0.144* | |
negative | 21 | 3 | 18 |
Responses to R-chemotherapy according to the C1qA [276] genotype
Best response to R-CHOP | C1qA
[276]
genotype | |||
---|---|---|---|---|
AA(%) | AG(%) | GG(%) | Total(%) | |
Complete response | 33 (89.2) | 26 (47.3) | 21 (56.8) | 80 (62.0) |
Partial response | 3 (8.1) | 20 (60.6) | 10 (27.0) | 33 (25.6) |
Overall response | 36 (97.3) | 46 (83.6) | 31 (83.8) | 113 (87.6) |
Stable disease | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
Progression | 1 (2.7) | 9 (16.4) | 6 (16.2) | 16 (12.4) |
Total | 37 (100) | 55 (100) | 37 (100) | 129 (100) |